



23 NOV 2004

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 1450
ALEXANDRIA, VA 22313-1450
www.uspto.gov

BROWDY & NEIMARK
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001

In re Application of:	:	
SELA, Yoram	:	DECISION ON PETITION TO
U.S. Application No.: 10/500,634	:	REVIVE ABANDONED
PCT No.: PCT/IL02/00890	:	APPLICATION UNDER 37
International Filing Date: 07 November 2002	:	CFR 1.137(b)
Priority Date: 13 November 2001	:	
Attorney's Docket No.: SELA5	:	
For: EXTENDED RELEASE COMPOSITIONS	:	
COMPRISING AS ACTIVE COMPOUND	:	
VENLAFAXINE	:	

The petition to revive under 37 CFR 1.137(b) filed 02 July 2004 in the above-captioned application is hereby **GRANTED** as follows:

Applicant's statement that "the entire delay in filing the required reply from the due date (May 13, 2004) for the reply until the filing of a grantable petition pursuant to this paragraph was unintentional" meets the requirements of 37 CFR 1.137(b)(3).

Applicants have now submitted the basic national fee and the requirements of 37 CFR 1.137(b) have been satisfied. Therefore, the request to revive the application is granted as to the national stage in the United States of America.

This application is being returned to the National Stage Processing Division of the Office of PCT Operations for further processing in accordance with this decision, including the issuance of a Notification Of Missing Requirements requiring submission of an oath or declaration in compliance with 37 CFR 1.497 and the surcharge for filing the declaration later than thirty months after the priority date.

Richard M. Ross
PCT Petitions Attorney
PCT Legal Office
Telephone: (571) 272-3296
Facsimile: (571) 273-0459